Understand the source comparison
Peptides for Alopecia: Comparison Analysis
GHK-Cu (copper tripeptide) Inhibits TGF-beta1, upregulates VEGF, reduces dermal papilla fibrosis 340 Da 18% density increase in 12-week trial (Int J Trichology 2015) 1.5% topical solution, daily application with microneedling Most studied peptide for follicle
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHK-Cu (copper tripeptide)
- Inhibits TGF-beta1, upregulates VEGF, reduces dermal papilla fibrosis
- 340 Da
- 18% density increase in 12-week trial (Int J Trichology 2015)
- 1.5% topical solution, daily application with microneedling
- Most studied peptide for follicle miniaturization reversal; requires consistent use for 16+ weeks
- Thymosin beta-4
- Activates follicle stem cells via laminin-5 expression, extends anagen phase
- 4963 Da
- Animal models show 25% faster anagen entry; limited human data
- 0.1–0.5 mg subcutaneous injection weekly or topical at 2% with penetration enhancer
- Promising stem cell activation mechanism but requires delivery optimization for topical use
- PTD-DBM
- Wnt/beta-catenin pathway agonist, reactivates telogen follicles
- 1200 Da
- Preclinical only. Follicle reactivation in mouse models
- Experimental. Not yet commercially available
- High theoretical potential for dormant follicle rescue; no established human safety profile
- Palmitoyl pentapeptide-4
- Stimulates collagen synthesis in dermal layer, improves follicle anchoring
- 500 Da
- Cosmetic trials show improved hair thickness (no follicle count data)
- 0.01–0.5% in commercial serums
- Supports structural integrity but doesn't address miniaturization or DHT signaling